Department of Defense PTSD Adaptive Platform Trial – Intervention D – SLS-002

This Phase II randomised, quadruple-blind, placebo-controlled trial (n=200) will assess the safety and efficacy of intranasal SLS-002 (ketamine, 78mg) for post-traumatic stress disorder (PTSD) in active-duty service members and veterans.

The study, part of the Department of Defense PTSD Adaptive Platform Trial, is sponsored by the Global Coalition for Adaptive Research. It employs an adaptive platform trial (APT) design, meaning multiple potential PTSD treatments are tested simultaneously with shared control groups.

Participants are randomly assigned to either the SLS-002 group or a placebo group (5:3 ratio). Treatment involves intranasal administration of SLS-002 twice weekly for eight weeks, then once weekly for four weeks. The primary outcome measure is the change in PTSD symptom severity over 12 weeks using the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R). Safety outcomes include monitoring suicidal thoughts, adverse events, and cardiovascular effects. The trial is expected to begin in June 2025 and conclude in September 2026, with study sites across the United States.

Topic PTSD
Compound Ketamine Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.